SCM
VRDN icon

Sterling Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Sterling Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3K Sell
986
-384
-28% -$11.4K ﹤0.01% 2047
2025
Q4 		$42.6K Buy
1,370
+230
+20% +$6.31K ﹤0.01% 1855
2025
Q3 		$24.6K Buy
1,140
+623
+121% +$11.2K ﹤0.01% 2043
2025
Q2 		$7.23K Buy
517
+121
+31% +$1.64K ﹤0.01% 2313
2025
Q1 		$5.34K Sell
396
-271
-41% -$4.62K ﹤0.01% 2139
2024
Q4 		$12.8K Buy
667
+567
+567% +$12.3K ﹤0.01% 2053
2024
Q3 		$2.27K Buy
+100
New +$1.64K ﹤0.01% 2128

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sterling Capital Management's VRDN Position: Q1 2026 in Review

Sterling Capital Management reduced its Viridian Therapeutics (VRDN) stake by 28% in Q1 2026, selling an estimated $11.4K and leaving 986 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2047.

Sterling Capital Management first reported a position in VRDN in Q3 2024 and has held it in 7 quarters since. The position peaked at $42.6K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Sterling Capital Management held 986 shares of Viridian Therapeutics worth $19.3K as of Q1 2026.
  • Sterling Capital Management sold 384 Viridian Therapeutics shares in Q1 2026, an estimated $11.4K.
  • Viridian Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2047 holding.
  • Sterling Capital Management first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Viridian Therapeutics position peaked at $42.6K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.